Form 4: Moderna Chief Legal Officer's Stock Vesting & Tax Withholding

Moderna's Chief Legal Officer, Shannon Thyme Klinger, reported the vesting of 2,630 performance-based restricted stock units and the sale of 1,334 shares for tax obligations.

Summary

• Shannon Thyme Klinger, Moderna's Chief Legal Officer, reported transactions on February 11, 2026.
• 2,630 shares of Common Stock vested from performance-based restricted stock units (2023 PSUs) that were granted on February 28, 2023.
• 1,334 shares were disposed of at a price of $41.99 per share to satisfy tax withholding obligations in connection with the vesting of the 2023 PSUs.
• Following these transactions, Klinger beneficially owns 54,527 shares of Moderna Common Stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, reflecting routine executive compensation activities (vesting and tax-related sales) rather than a discretionary action or a reflection of the company's immediate operational performance.

Positives

• Vesting of 2,630 performance-based restricted stock units for the Chief Legal Officer, indicating the fulfillment of compensation terms.

Negatives

• No direct negatives for the company's operational or financial performance are indicated by this routine transaction.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The reported transaction is the vesting of performance-based restricted stock units granted to the reporting person on February 28, 2023.
• Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vesting of the 2023 PSUs.

Industry Context

StockSavvy.ai notes that routine insider transactions like Form 4 filings for RSU vesting and tax withholding are common across the biotechnology and pharmaceutical industries, reflecting standard executive compensation practices. These filings typically do not indicate a change in company strategy or financial health but rather the execution of pre-established compensation plans.

Comparison to Industry Standards

• The vesting of performance-based restricted stock units (PSUs) is a standard executive compensation practice in the biotechnology and pharmaceutical sectors, similar to companies like Pfizer, Johnson & Johnson, and AstraZeneca, which use such equity awards to align executive incentives with long-term company performance.
• The practice of withholding shares to cover tax obligations upon vesting is also a common and efficient method for executives across industries to manage their tax liabilities, consistent with practices observed at major tech firms like Apple or financial institutions like JPMorgan Chase.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine compensation event, but it reflects the ongoing dilution from equity compensation plans.
• Management: The Chief Legal Officer benefits from the vesting of equity compensation as part of their remuneration package.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event involving the vesting of restricted stock units and the sale of shares for tax purposes. Such transactions are pre-scheduled and do not reflect a discretionary investment decision by the insider or new information about the company's operational performance or future outlook. Therefore, it does not provide a basis for altering an existing investment recommendation.

Keywords

Moderna, MRNA, Form 4, insider transaction, stock vesting, restricted stock units, RSU, tax withholding, Shannon Thyme Klinger, Chief Legal Officer